HK1054947A1 - Adnf mixtures for enhancing learning and memory. - Google Patents
Adnf mixtures for enhancing learning and memory.Info
- Publication number
- HK1054947A1 HK1054947A1 HK03106025A HK03106025A HK1054947A1 HK 1054947 A1 HK1054947 A1 HK 1054947A1 HK 03106025 A HK03106025 A HK 03106025A HK 03106025 A HK03106025 A HK 03106025A HK 1054947 A1 HK1054947 A1 HK 1054947A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- memory
- adnf
- mixtures
- learning
- enhancing learning
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20894400P | 2000-05-31 | 2000-05-31 | |
US26780501P | 2001-02-08 | 2001-02-08 | |
PCT/US2001/017758 WO2001092333A2 (en) | 2000-05-31 | 2001-05-31 | Use of adnf for enhancing learning and memory |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1054947A1 true HK1054947A1 (en) | 2003-12-19 |
Family
ID=26903662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK03106025A HK1054947A1 (en) | 2000-05-31 | 2003-08-22 | Adnf mixtures for enhancing learning and memory. |
Country Status (12)
Country | Link |
---|---|
US (2) | US7427598B2 (de) |
EP (1) | EP1285000B1 (de) |
JP (1) | JP4440536B2 (de) |
CN (1) | CN1444600A (de) |
AT (1) | ATE283286T1 (de) |
AU (2) | AU2001275111B2 (de) |
CA (1) | CA2410735A1 (de) |
DE (1) | DE60107416T2 (de) |
HK (1) | HK1054947A1 (de) |
MX (1) | MXPA02011923A (de) |
NZ (1) | NZ522821A (de) |
WO (1) | WO2001092333A2 (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6613740B1 (en) * | 1997-02-07 | 2003-09-02 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Activity dependent neurotrophic factor III (ADNF III) |
US7384908B1 (en) * | 1999-08-18 | 2008-06-10 | National Institute Of Health | Orally active peptides that prevent cell damage and death |
NZ522821A (en) * | 2000-05-31 | 2004-08-27 | Us Gov Health & Human Serv | Use of activity-dependent neurotrophic factor-derived polypeptides for enhancing learning and memory: pre- and post-natal administration |
WO2003022226A2 (en) * | 2001-09-12 | 2003-03-20 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Neurotrophic components of the adnf i complex |
KR101228204B1 (ko) * | 2003-02-10 | 2013-01-31 | 투-비비비 홀딩 비.브이. | 염증성 상태 하에 있는 뇌-혈관 장벽에서 차등 발현되는핵산 |
US7960334B2 (en) | 2003-03-12 | 2011-06-14 | Ramot At Tel-Aviv University Ltd. | Use of ADNF III polypeptides for treating mental diseases and disorders, including schizophrenia |
JP4878551B2 (ja) * | 2004-04-08 | 2012-02-15 | 貞和 相磯 | 運動ニューロン疾患治療薬 |
JP5174653B2 (ja) | 2005-03-23 | 2013-04-03 | ラモト アト テルーアビブ ユニバーシティー リミテッド | 末梢神経毒症状を処置するためのadnfポリペプチドの使用 |
TWI303567B (en) * | 2005-12-20 | 2008-12-01 | Ind Tech Res Inst | Oligopeptide, derivative thereof, and pharmaceutical composition comprising the same |
US20070185035A1 (en) * | 2005-12-23 | 2007-08-09 | Nastech Pharmaceutical Company Inc. | Enhanced mucosal administration of neuroprotective peptides |
WO2007096859A2 (en) | 2006-02-24 | 2007-08-30 | Ramot At Tel-Aviv University Ltd. | Protection of the retina against laser injury by adnf peptides such as nap and sal |
KR20100063719A (ko) * | 2007-08-24 | 2010-06-11 | 라모트 앳 텔-아비브 유니버시티 리미티드 | Nap 유사 및 sal 유사 펩티드 모의체를 사용한 신경보호 |
EP2467397A1 (de) | 2009-08-17 | 2012-06-27 | Ramot at Tel-Aviv University Ltd. | Nap-alpha-aminoisobuttersäureanalogon mit nervenschützender wirkung |
US9518994B2 (en) | 2010-01-06 | 2016-12-13 | Ramot At Tel Aviv University | Method for diagnosing and monitoring schizophrenia and tauopathies |
WO2012015910A2 (en) * | 2010-07-28 | 2012-02-02 | Allon Therapeutics Inc. | Use of adnf polypeptides for treating neurodegenerative diseases |
EP3377089B1 (de) * | 2015-11-18 | 2020-04-08 | Herantis Pharma Plc | Zusammensetzungen mit cdnf zur verwendung bei der intranasalen behandlung von erkrankungen des zentralnervensystems |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4587046A (en) * | 1982-05-18 | 1986-05-06 | The Regents Of The University Of California | Drug-carrier conjugates |
DE69233492D1 (de) | 1991-04-22 | 2005-04-28 | Nasa | Aktivitätsabhängiger neurotropher faktor |
US6174862B1 (en) | 1991-04-22 | 2001-01-16 | Ramot University Authority For Applied Research And Industrial Development, Ltd. | Neurotrophic peptides of activity dependent neurotrophic factor |
US6310040B1 (en) * | 1991-11-08 | 2001-10-30 | Cephalon, Inc. | Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs |
AU4238493A (en) * | 1992-05-08 | 1993-12-13 | Thomas Jefferson University | IGF-1 analogs |
US6613740B1 (en) | 1997-02-07 | 2003-09-02 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Activity dependent neurotrophic factor III (ADNF III) |
US6933277B2 (en) | 1999-03-12 | 2005-08-23 | The United States Of America As Represented By The Department Of Health And Human Services | Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides |
US7384908B1 (en) * | 1999-08-18 | 2008-06-10 | National Institute Of Health | Orally active peptides that prevent cell damage and death |
ATE266044T1 (de) | 1999-08-18 | 2004-05-15 | Univ Ramot | Oral wirksame peptide, die zellschädigung und zelltod verhindern |
NZ522821A (en) * | 2000-05-31 | 2004-08-27 | Us Gov Health & Human Serv | Use of activity-dependent neurotrophic factor-derived polypeptides for enhancing learning and memory: pre- and post-natal administration |
-
2001
- 2001-05-31 NZ NZ52282101A patent/NZ522821A/en not_active IP Right Cessation
- 2001-05-31 EP EP01941783A patent/EP1285000B1/de not_active Expired - Lifetime
- 2001-05-31 DE DE60107416T patent/DE60107416T2/de not_active Expired - Lifetime
- 2001-05-31 AT AT01941783T patent/ATE283286T1/de not_active IP Right Cessation
- 2001-05-31 AU AU2001275111A patent/AU2001275111B2/en not_active Ceased
- 2001-05-31 CA CA002410735A patent/CA2410735A1/en not_active Abandoned
- 2001-05-31 CN CN01810354A patent/CN1444600A/zh active Pending
- 2001-05-31 US US10/296,849 patent/US7427598B2/en not_active Expired - Fee Related
- 2001-05-31 JP JP2002500944A patent/JP4440536B2/ja not_active Expired - Fee Related
- 2001-05-31 WO PCT/US2001/017758 patent/WO2001092333A2/en active IP Right Grant
- 2001-05-31 AU AU7511101A patent/AU7511101A/xx active Pending
- 2001-05-31 MX MXPA02011923A patent/MXPA02011923A/es active IP Right Grant
-
2003
- 2003-08-22 HK HK03106025A patent/HK1054947A1/xx not_active IP Right Cessation
-
2008
- 2008-08-25 US US12/197,986 patent/US20090203615A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US7427598B2 (en) | 2008-09-23 |
DE60107416T2 (de) | 2005-12-01 |
AU7511101A (en) | 2001-12-11 |
EP1285000A2 (de) | 2003-02-26 |
JP2003535105A (ja) | 2003-11-25 |
WO2001092333A2 (en) | 2001-12-06 |
DE60107416D1 (de) | 2004-12-30 |
NZ522821A (en) | 2004-08-27 |
WO2001092333A3 (en) | 2002-05-30 |
CA2410735A1 (en) | 2001-12-06 |
US20040048801A1 (en) | 2004-03-11 |
MXPA02011923A (es) | 2004-09-06 |
AU2001275111B2 (en) | 2006-07-06 |
EP1285000B1 (de) | 2004-11-24 |
ATE283286T1 (de) | 2004-12-15 |
CN1444600A (zh) | 2003-09-24 |
JP4440536B2 (ja) | 2010-03-24 |
US20090203615A1 (en) | 2009-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1054947A1 (en) | Adnf mixtures for enhancing learning and memory. | |
DK1482042T3 (da) | Aktive og inaktive CC-kemokinreceptorer og nukleinsyremolekyler der koder for receptoren | |
WO2000001845A3 (de) | Verfahren zur frühen diagnose von carcinomen | |
DE60019458D1 (de) | Stabilisierendes verdünnungsmittel für polypeptide und antigene | |
HK1102197A1 (en) | Hif prolyl hydroxylase activity assay | |
WO2003104418A3 (en) | RECONSTITUTED POLYPEPTIDES | |
IL177638A0 (en) | Tie receptor tyrosine kinase ligand homologues | |
MXPA02005797A (es) | Metodos y dispositivos electroquimicos para su uso en la determinacion de concentraciones de analitos con hematocrito corregido. | |
DE59903410D1 (de) | Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung | |
MXPA02012743A (es) | Moleculas tipo il-17 y usos de las mismas. | |
WO2002046228A3 (en) | Receptor for b. anthracis toxin | |
WO2005012337A3 (en) | Antigenic peptides of sars coronavirus and uses thereof | |
YU18903A (sh) | Fuzioni proteini od inhibitora protivtela citokin- citokin (selektokin) kao ciljno specifični pro-lek | |
MX9602557A (es) | Proteinas de higado de mamifero y su uso en oncologia. | |
WO2005016233A3 (en) | Botulinum neurotoxin b receptors and use thereof | |
WO2003068940A3 (en) | Complexes and methods of using same | |
AU2002304163A1 (en) | Polypeptide unstabilizing protein in cells under aerobic conditions and DNA encoding the same | |
WO1999037758A3 (en) | Expression of proteolytically-sensitive peptides | |
WO2004060309A3 (en) | Methods of treating and/or preventing autoimmune diseases | |
ZA99445B (en) | Isolated, polypeptides which bind to HLA-A29 molecules nucleic acid, the molecules encoding these, and uses thereof. | |
DE69930370D1 (de) | Testisspezifische, menschliche proteinase, svph1-8 | |
UA31167A (uk) | Спосіб визначення ортофосфату у воді | |
EP2290080A3 (de) | Zusammensetzungen und Methoden für Diagnose und Behandlung der Psoriasis (Schuppenflechte) | |
ATA14412002A (de) | Nutzfahrzeug oder nutzfahrzeuganhänger | |
Crow | EPA Seeks Additional Funds for 2001 Water Programs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHPA | Change of a particular in the register (except of change of ownership) | ||
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20140531 |